From: From animal models to human disease: a genetic approach for personalized medicine in ALS
Species | Mutation | Age at onset (weeks) | Survival (weeks) | Phenotype | References | |||
---|---|---|---|---|---|---|---|---|
Paralysis | Cognitive symptoms | Neuropathological findings and particularities | Gliosis | |||||
Mice | hSOD1WT | 58–70 | normal | N | nd | Mitochondria vacuolization and swelling,, spinocerebellar axonal degeneration, 20-30 % MN loss | Y | [69] |
 | hSOD1WT | 36 | 52 | Y | nd | SOD1 inclusions, vacuolization, MN loss, glial cell aggregates | Y | [71] |
 | A4V | >85 | normal | N | N | nd | N | [70] |
 | A4V/SOD1WT | 35 | 48 | Y | nd | SOD1 inclusions, MN degeneration | Y | [70] |
 | G37R | 15–17 | 25–29 | Y | Learning deficit | MBV, LMN first affected, raised somatosensory thresholds | Y | |
 | H46R | 20 | 24 | Y | nd | LBHI, ubiquitin, SOD1 inclusions | Y | [244] |
 | H46R/H48Q | 17–26 | nd | Y | nd | HI, ubiquitin | nd | [245] |
 | H46R/H48Q/ | 35–52 | nd | Y | nd | Fibrillary SOD1-ubiquitin inclusions | Y | [246] |
 | H63G/H120G |  |  |  |  |  |  |  |
 | D83Ga | 15 | 70–84 | N | nd | Sensory deficit, tremors, 20 % LMN and UMN loss | Y | [78] |
 | L84V | 21–26 | 26–30 | Y | nd | nd | nd | [247] |
 | G85R | 35–43 | 37–45 | Y | nd | Rapid progression, SOD1-ubiquitin inclusions in neurons and astrocytes | Y | [248] |
 | G85R/SOD1WT | 16–21 | 23–30 | Y | nd | SOD1 aggregates | Y | [249] |
 | G86Rb | 13–17 | 17 | Y | nd | Rapid progression (5 days) | nd | [250] |
 | D90A | 52 | 61 | Y | nd | Distended bladder, SOD1 inclusions, MN loss | Y | [75] |
 | G93A | 13–17 | 17–26 | Y | Y | MN loss, SOD1 aggregates, NMJ loss before onset | Y | |
 | G93A/SOD1WT | 20–23 | 25–30 | Y | nd | Vacuoles, MN loss | Y | [69] |
 | Thy1.2-G93Ac | 54- >104 | 62- >104 | N | nd | SOD1 aggregates | Y | [79] |
 | L126Z | 28–44 | 47 | Y | nd | Eosinophilic inclusion, MN loss, ubiquitin inclusions | Y | |
 | G127X | 35 | 36 | Y | nd | Rapid disease course, SOD1-ubiquitin inclusions | Y | [252] |
Rats | H46R | 20 | 24 | Y | nd | MN loss, LBHI, SOD1-ubiquitin aggregates | Y | [253] |
 | G93A | 16 | 17 | Y | nd | MN loss, vacuoles, SOD1-ubiquitin inclusions | Y | |
Dogs | T18S | 7Â years | 21 monthsd | Y | nd | SOD1 aggregates No neuronal cell body loss, UMN and LMN signs, sensory impairment | Y | [86] |
 | E40K | >5 years | 6 months–3 yearsd | Y | nd |  | Y | [85] |
Zebrafish | A4Ve | 30Â h | nd | N | nd | Motor axonopathy and abnormal branching | nd | [90] |
 | G37Re | 30 h | nd | N | nd |  | nd | [90] |
 | G93Ae | 30 h | nd | N | nd |  | nd | [90] |
 | G93A | 20–60 | nd | N | nd | Increase time resting but no swim speed change, NMJ loss, 50 % MN loss | nd | [91] |
 | G93Rf | 12 months | 18–27 months | partial | nd | NMJ defects, MN loss, swimming incapacity, vacuolated mitochondria | nd | [92] |
Fruit flies | hSOD1WT | 3 | normal | N | nd | Loss of climbing, no MN loss, decrease synaptic transmission in giant fiber motor pathway | HSP70 stress response | [93] |
 | A4V | 4 | normal | N | nd |  |  | [93] |
 | G85R | 2 | normal | N | nd |  |  | [93] |
 | D83S | 4 | normal | N | nd | Mitochondrial pathology, decreased physical activity | nd | [255] |
Nematodes | hSOD1WT | 10 days | 10–20 D | Y | nd | Reduction in thrash number | nd | [95] |
 | G85R | 10 days | 10–20 D | Y | nd | Forward movement defect, SOD1 inclusions | nd | [95] |
 | G93A | 2 days | nd | Y | nd | SOD1 inclusions in MN, axons guidance defects | nd | |
 | C6S/C57S/ | normal | normal | N | nd | No phenotype | nd | [95] |
 | C111S/C146S |  |  |  |  |  |  |  |
Pigs | G93A | 12 | normal | N | nd | MN loss at 8Â months, Intra-nuclear SOD1-ubiquitin inclusions, running deficit, fibrillation potentials and positive sharp waves at EMG | Y | [99] |